Paid Clinical Trials for Blood Disorders, Myelodysplastic Syndromes

Paid Clinical Trials and Focus Groups by Category

Find Paid Clinical Trials

Find Paid Clinical Trials All Categories ... by Medical Condition » ... Blood Disorders » ... Myelodysplastic Syndromes


  • A Clinical Trial of OXi4503 for Relapsed and Refractory Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS)

    Conditions:   Leukemia, Myelogenous, Acute;   Myelodysplastic Syndromes
    Intervention:   Drug: Oxi4503
    Sponsor:   University of Florida
    Not yet recruiting - verified March 2010
  • Azacitidine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant

    Conditions:   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With T(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With T(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With T(8;21)(q22;q22);   Childhood Myelodysplastic Syndromes;   Chronic Myelomonocytic Leukemia;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes
    Interventions:   Drug: azacitidine;   Drug: gemtuzumab ozogamicin
    Sponsor:   Fred Hutchinson Cancer Research Center
    Not yet recruiting - verified March 2010
  • Presence of Donor-Derived DNA in Semen Samples From Cancer Survivors Who Underwent Donor Stem Cell Transplant

    Conditions:   Cancer Survivor;   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Neuroblastoma;   Testicular Germ Cell Tumor
    Interventions:   Genetic: DNA analysis;   Genetic: polymerase chain reaction;   Other: flow cytometry;   Other: laboratory biomarker analysis
    Sponsors:   Vanderbilt-Ingram Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified February 2010
  • Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

    Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With T(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With T(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With T(8;21)(q22;q22);   Atypical Chronic Myeloid Leukemia;   Blastic Phase Chronic Myelogenous Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   De Novo Myelodysplastic Syndromes;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Myelodysplastic/Myeloproliferative Disease, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Burkitt Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Splenic Marginal Zone Lymphoma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Multiple Myeloma;   Stage III Small Lymphocytic Lymphoma;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Small Lymphocytic Lymphoma
    Interventions:   Drug: plerixafor;   Biological: filgrastim;   Procedure: peripheral blood stem cell transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation
    Sponsor:   Fred Hutchinson Cancer Research Center
    Not yet recruiting - verified February 2010
  • Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic Syndrome

    Conditions:   Acute Lymphocytic Leukemia;   Acute Myeloid Leukemia;   Myelodysplastic Syndrome;   Chronic Myelogenous Leukemia
    Interventions:   Drug: bortezomib;   Drug: belinostat;   Other: laboratory biomarker analysis;   Genetic: western blotting;   Other: pharmacological study;   Other: flow cytometry
    Sponsors:   Virginia Commonwealth University;   National Cancer Institute (NCI)
    Not yet recruiting - verified February 2010
  • A Pediatric Study of a Plerixafor Containing Regimen In Second Allogenic Stem Cell Transplantation

    Conditions:   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Chronic Myeloid Leukemia;   Myelodysplastic Syndrome;   Non-Hodgkin's Lymphoma
    Intervention:   Drug: Plerixafor
    Sponsor:   St. Jude Children's Research Hospital
    Not yet recruiting - verified March 2010
  • Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

    Condition:   Myelodysplastic Syndrome
    Interventions:   Drug: Ezatiostat Hydrochloride;   Drug: Lenalidomide (Revlimid®)
    Sponsor:   Telik
    Recruiting - verified February 2010
  • Rituximab in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

    Conditions:   Graft Versus Host Disease;   Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Blastic Phase Chronic Myelogenous Leukemia;   Contiguous Stage II Adult Burkitt Lymphoma;   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Contiguous Stage II Adult Lymphoblastic Lymphoma;   Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Contiguous Stage II Mantle Cell Lymphoma;   Contiguous Stage II Marginal Zone Lymphoma;   Contiguous Stage II Small Lymphocytic Lymphoma;   De Novo Myelodysplastic Syndromes;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Burkitt Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Relapsing Chronic Myelogenous Leukemia;   Secondary Myelodysplastic Syndromes;   Splenic Marginal Zone Lymphoma;   Stage I Adult Burkitt Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Diffuse Small Cleaved Cell Lymphoma;   Stage I Adult Immunoblastic Large Cell Lymphoma;   Stage I Adult Lymphoblastic Lymphoma;   Stage I Adult T-cell Leukemia/Lymphoma;   Stage I Chronic Lymphocytic Leukemia;   Stage I Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage I Marginal Zone Lymphoma;   Stage I Mycosis Fungoides/Sezary Syndrome;   Stage I Small Lymphocytic Lymphoma;   Stage II Adult T-cell Leukemia/Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage II Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage II Mycosis Fungoides/Sezary Syndrome;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Adult T-cell Leukemia/Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Mycosis Fungoides/Sezary Syndrome;   Stage III Small Lymphocytic Lymphoma;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Adult T-cell Leukemia/Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Mycosis Fungoides/Sezary Syndrome;   Stage IV Small Lymphocytic Lymphoma;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Adult Acute Myeloid Leukemia;   Waldenstrom Macroglobulinemia
    Interventions:   Drug: rituximab;   Drug: mycophenolate mofetil;   Drug: tacrolimus;   Drug: anti-thymocyte globulin;   Procedure: allogeneic hematopoietic stem cell transplantation;   Other: laboratory biomarker analysis;   Biological: graft versus host disease prophylaxis/therapy;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: busulfan;   Radiation: total-body irradiation;   Biological: graft-versus-tumor induction therapy;   Biological: immunosuppressive therapy
    Sponsor:   University of Nebraska
    Recruiting - verified March 2010
  • Donor Lymphocytes in Preventing and Treating Cytomegalovirus Infection or Adenovirus Infection in Patients Who Have Undergone Umbilical Cord Blood Transplant

    Condition:   Cancer
    Interventions:   Biological: allogeneic CMV/AdV-specific cytotoxic T lymphocytes;   Other: laboratory biomarker analysis
    Sponsors:   Baylor College of Medicine;   National Cancer Institute (NCI)
    Recruiting - verified December 2009
  • To Demonstrate Superiority of Decitabine Over Azacitidine in Subjects With Intermediate- or High-risk MDS.

    Condition:   Myelodysplastic Syndromes
    Interventions:   Drug: decitabine;   Drug: azacitidine
    Sponsor:   Eisai Inc.
    Not yet recruiting - verified February 2010
  • Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers

    Conditions:   Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
    Interventions:   Genetic: cytogenetic analysis;   Genetic: fluorescence in situ hybridization
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group
    Recruiting - verified March 2010
  • Methemoglobinemia in Young Patients With Hematologic Cancer or Aplastic Anemia Treated With Dapsone

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Methemoglobinemia;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Nonmalignant Neoplasm
    Interventions:   Drug: chemotherapy;   Drug: dapsone;   Other: medical chart review;   Procedure: assessment of therapy complications
    Sponsors:   Vanderbilt-Ingram Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified December 2009
  • Flu Vaccine in Preventing Influenza Infection in Healthy Volunteers and in Patients Who Have Undergone Stem Cell Transplant

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Nonmalignant Neoplasm
    Interventions:   Biological: trivalent influenza vaccine;   Other: immunoenzyme technique;   Other: laboratory biomarker analysis
    Sponsors:   Beckman Research Institute;   National Cancer Institute (NCI)
    Recruiting - verified August 2009
  • Influenza Vaccine in Preventing Flu in Patients Who Have Undergone Stem Cell Transplant and in Healthy Volunteers

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Nonmalignant Neoplasm;   Viral Infection
    Interventions:   Other: cytology specimen collection procedure;   Other: fluorescent antibody technique;   Procedure: assessment of therapy complications
    Sponsors:   Beckman Research Institute;   National Cancer Institute (NCI)
    Recruiting - verified August 2009
  • Home Visits or Standard Therapy in Treating Patients Undergoing Donor Stem Cell Transplant for Hematologic Cancer

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Psychosocial Effects of Cancer and Its Treatment;   Therapy-related Toxicity
    Interventions:   Behavioral: exercise intervention;   Behavioral: telephone-based intervention;   Dietary Supplement: dietary intervention;   Other: educational intervention;   Other: questionnaire administration;   Procedure: allogeneic bone marrow transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: assessment of therapy complications;   Procedure: peripheral blood stem cell transplantation;   Procedure: psychosocial assessment and care;   Procedure: quality-of-life assessment;   Procedure: standard follow-up care
    Sponsors:   Beckman Research Institute;   National Cancer Institute (NCI)
    Recruiting - verified July 2009
  • Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant

    Condition:   Cancer
    Interventions:   Genetic: polymorphism analysis;   Other: laboratory biomarker analysis
    Sponsors:   Vanderbilt-Ingram Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified June 2009
  • Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

    Condition:   Leukemia
    Interventions:   Drug: Vorinostat;   Drug: Azacitidine
    Sponsors:   M.D. Anderson Cancer Center;   Merck
    Recruiting - verified March 2010
  • A Study Of PF-04449913 In Select Hematologic Malignancies Or With Dasatinib In Chronic Myeloid Leukemia (CML)

    Condition:   Hematologic Malignancies
    Interventions:   Drug: PF-04449913;   Drug: dasatinib
    Sponsor:   Pfizer
    Recruiting - verified February 2010
  • Genetic Susceptibility and Risk of Second Cancers in Patients Who Have Undergone Stem Cell Transplant for Cancer

    Condition:   Cancer
    Interventions:   Genetic: DNA analysis;   Genetic: polymorphism analysis;   Other: laboratory biomarker analysis;   Other: medical chart review;   Other: questionnaire administration;   Procedure: assessment of therapy complications;   Procedure: evaluation of cancer risk factors
    Sponsors:   Vanderbilt-Ingram Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified April 2009
  • 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Unspecified Adult Solid Tumor, Protocol Specific
    Intervention:   Other: 3'-deoxy-3'-[18F]fluorothymidine
    Sponsors:   Barbara Ann Karmanos Cancer Institute;   National Cancer Institute (NCI)
    Recruiting - verified September 2009
  • Collecting and Storing Blood and Bone Marrow Samples From Patients With Hematologic Cancer

    Conditions:   Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
    Intervention:   Other: biologic sample preservation procedure
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified March 2010
  • Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD

    Conditions:   Graft Versus Host Disease;   Leukemia;   Myelodysplastic Syndromes
    Interventions:   Drug: Fludarabine Phosphate;   Drug: Tacrolimus;   Drug: Thiotepa;   Radiation: Total-Body Irradiation (TBI);   Device: Magnetic-Activated Cell Sorter (CliniMACS, Miltenyi)
    Sponsors:   Yale University;   National Cancer Institute (NCI);   Fred Hutchinson Cancer Research Center
    Recruiting - verified March 2010
  • Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)

    Conditions:   Advanced Myelodysplastic Syndrome;   Myelodysplastic Syndrome;   Secondary Acute Myeloid Leukemia After MDS;   Thrombocytopenia
    Interventions:   Drug: eltrombopag olamine;   Other: Placebo
    Sponsor:   GlaxoSmithKline
    Recruiting - verified March 2010
  • Collecting and Storing Blood, Bone Marrow, and Other Samples From Patients With Acute Leukemia, Chronic Leukemia, or Myelodysplastic Syndromes

    Conditions:   Leukemia;   Lymphoma;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
    Intervention:   Other: biologic sample preservation procedure
    Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
    Recruiting - verified March 2010
  • Collecting and Storing Tissue and DNA Samples From Patients Undergoing a Donor Stem Cell Transplant

    Conditions:   Breast Cancer;   Chronic Myeloproliferative Disorders;   Gestational Trophoblastic Tumor;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Neuroblastoma;   Ovarian Cancer;   Testicular Germ Cell Tumor
    Interventions:   Genetic: gene expression analysis;   Genetic: microarray analysis;   Genetic: polymorphism analysis;   Genetic: proteomic profiling;   Other: flow cytometry;   Other: immunologic technique;   Other: laboratory biomarker analysis;   Procedure: biopsy
    Sponsors:   Vanderbilt-Ingram Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified October 2008
  • Collecting and Storing Blood Samples From Patients With Cancer

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Nonmalignant Neoplasm;   Unspecified Adult Solid Tumor, Protocol Specific;   Unspecified Childhood Solid Tumor, Protocol Specific
    Intervention:   Other: biologic sample preservation procedure
    Sponsors:   Cancer Institute of New Jersey;   National Cancer Institute (NCI)
    Recruiting - verified August 2008
  • Studying Fentanyl in Patients With Cancer

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Precancerous Condition;   Unspecified Adult Solid Tumor, Protocol Specific
    Interventions:   Drug: fentanyl citrate;   Other: pharmacological study
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified July 2009
  • Blood Samples From Patients With Cancer Treated on a Clinical Trial to Control Nausea and Vomiting During Donor Stem Cell Transplant

    Conditions:   Breast Cancer;   Chronic Myeloproliferative Disorders;   Gestational Trophoblastic Tumor;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Nausea and Vomiting;   Neuroblastoma;   Ovarian Cancer;   Testicular Germ Cell Tumor
    Interventions:   Other: immunoenzyme technique;   Other: laboratory biomarker analysis;   Other: medical chart review
    Sponsors:   OHSU Knight Cancer Institute;   National Cancer Institute (NCI)
    Recruiting - verified June 2009
  • Sunitinib Malate in Treating HIV-Positive Patients With Cancer Undergoing Highly Active Antiretroviral Therapy

    Conditions:   Chronic Myeloproliferative Disorders;   Kidney Cancer;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Nonneoplastic Condition;   Unspecified Adult Solid Tumor, Protocol Specific
    Interventions:   Drug: sunitinib malate;   Other: liquid chromatography;   Other: mass spectrometry;   Other: pharmacological study
    Sponsors:   AIDS Associated Malignancies Clinical Trials Consortium;   National Cancer Institute (NCI)
    Recruiting - verified March 2010
  • Collecting and Storing Tissue From Young Patients With Cancer

    Condition:   Cancer
    Interventions:   Genetic: DNA analysis;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: biologic sample preservation procedure;   Other: flow cytometry;   Other: laboratory biomarker analysis
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified March 2010
  • Early Detection of Graft-Versus-Host Disease in Patients Undergoing a Donor Bone Marrow Transplant

    Condition:   Cancer
    Interventions:   Genetic: RNA analysis;   Genetic: gene expression analysis;   Genetic: protein expression analysis;   Other: laboratory biomarker analysis;   Procedure: allogeneic bone marrow transplantation
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting - verified August 2009
  • Iron Overload in Patients Undergoing Donor Stem Cell Transplant

    Condition:   Cancer
    Interventions:   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: assessment of therapy complications;   Procedure: magnetic resonance imaging
    Sponsors:   Masonic Cancer Center, University of Minnesota;   National Cancer Institute (NCI)
    Recruiting - verified August 2009
  • Fludarabine, Melphalan, Total-Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders

    Conditions:   Chronic Myeloproliferative Disorders;   Fanconi Anemia;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Nonmalignant Neoplasm;   Paroxysmal Nocturnal Hemoglobinuria
    Interventions:   Biological: anti-thymocyte globulin;   Biological: graft-versus-tumor induction therapy;   Drug: fludarabine phosphate;   Drug: melphalan;   Procedure: allogeneic hematopoietic stem cell transplantation;   Radiation: total-body irradiation
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
    Recruiting - verified November 2009
  • Study of Stem Cell Transplant for Leukemia and Myelodysplatic Syndroms Using Clofarabine and Busulfan Regimen

    Conditions:   Leukemia;   Myelodysplastic Syndrome
    Intervention:   Drug: Clofarabine/Busulfan
    Sponsors:   Baylor Research Institute;   Genzyme
    Recruiting - verified February 2010
  • Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

    Conditions:   Anemia;   Leukemia;   Myelodysplastic Syndromes
    Interventions:   Biological: epoetin alfa;   Drug: lenalidomide
    Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified March 2010
  • Stress Management Intervention for Caregivers of Patients Undergoing Bone Marrow Transplant

    Conditions:   Breast Cancer;   Chronic Myeloproliferative Disorders;   Gestational Trophoblastic Tumor;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Neuroblastoma;   Ovarian Cancer;   Testicular Germ Cell Tumor
    Interventions:   Other: educational intervention;   Other: laboratory biomarker analysis;   Other: questionnaire administration;   Other: survey administration;   Procedure: psychosocial assessment and care;   Procedure: stress management therapy;   Procedure: support group therapy
    Sponsors:   University of Colorado, Denver;   National Cancer Institute (NCI)
    Recruiting - verified January 2009
  • Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Myelodysplastic Syndromes;   Nonmalignant Neoplasm
    Interventions:   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Drug: pentostatin;   Genetic: cytogenetic analysis;   Genetic: fluorescence in situ hybridization;   Genetic: protein analysis;   Other: flow cytometry;   Other: immunoenzyme technique;   Other: laboratory biomarker analysis;   Other: reduced-intensity transplant conditioning procedure;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: total-body irradiation
    Sponsors:   University of Nebraska;   National Cancer Institute (NCI)
    Recruiting - verified July 2009
  • Immunologic Diagnostic Blood Test in Predicting Side-Effects in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Other Diseases

    Conditions:   Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Infection;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Neuroblastoma;   Therapy-related Toxicity
    Interventions:   Biological: immunosuppressive therapy;   Other: immunological diagnostic method;   Procedure: allogeneic hematopoietic stem cell transplantation
    Sponsors:   Beckman Research Institute;   National Cancer Institute (NCI)
    Recruiting - verified June 2009
  • Thymoglobulin and Cyclosporine in Patients With Aplastic Anemia or Myelodysplastic Syndrome

    Conditions:   Myelodysplastic Syndrome;   Aplastic Anemia
    Interventions:   Drug: Thymoglobulin;   Drug: Cyclosporine;   Drug: Methylprednisolone;   Drug: G-CSF
    Sponsors:   M.D. Anderson Cancer Center;   Genzyme
    Recruiting - verified March 2010
  • A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies

    Conditions:   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Chronic Myelogenous Leukemia;   Chronic Lymphocytic Leukemia;   Multiple Myeloma;   Waldenstrom's Macroglobulinemia;   Myelodysplastic Syndrome;   Philadelphia Chromosome-negative CML;   Myeloid Metaplasia;   Myelofibrosis;   Advanced Polycythemia;   Non-Hodgkins Lymphoma
    Intervention:   Drug: TAK-901
    Sponsor:   Millennium Pharmaceuticals, Inc.
    Recruiting - verified March 2010
  • Total Marrow and Total Lymph Node Irradiation, Fludarabine, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematological Cancer That Has Not Responded to Treatment

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
    Interventions:   Drug: fludarabine phosphate;   Drug: melphalan;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Radiation: intensity-modulated radiation therapy;   Radiation: tomotherapy;   Radiation: total marrow irradiation;   Radiation: total nodal irradiation
    Sponsors:   Beckman Research Institute;   National Cancer Institute (NCI)
    Recruiting - verified June 2009
  • Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Stem Cell Transplant Cope With Late Complications

    Condition:   Cancer
    Interventions:   Other: internet-based intervention;   Other: questionnaire administration;   Procedure: assessment of therapy complications;   Procedure: fatigue assessment and management;   Procedure: management of therapy complications;   Procedure: psychosocial assessment and care
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified August 2009
  • Natural Killer Cells and Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancer

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
    Interventions:   Biological: natural killer cell therapy;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Drug: tacrolimus;   Procedure: allogeneic bone marrow transplantation;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Radiation: total-body irradiation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified August 2009
  • Early Administration of Antithymocyte Globulin Followed By Cyclophosphamide, Busulfan, and Fludarabine Before a Donor Stem Cell Transplant in Treating Patients With Hematological Cancer or Kidney Cancer

    Conditions:   Chronic Myeloproliferative Disorders;   Kidney Cancer;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
    Interventions:   Biological: anti-thymocyte globulin;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: methotrexate;   Drug: tacrolimus;   Genetic: polymerase chain reaction;   Other: pharmacological study;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation
    Sponsor:   Blood and Marrow Transplant Group of Georgia
    Recruiting - verified June 2009
  • A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Neuroblastoma;   Ovarian Cancer;   Psychosocial Effects of Cancer and Its Treatment;   Sarcoma
    Interventions:   Other: educational intervention;   Other: informational intervention;   Other: internet-based intervention;   Other: questionnaire administration;   Other: study of socioeconomic and demographic variables;   Other: survey administration;   Procedure: psychosocial assessment and care;   Procedure: quality-of-life assessment;   Procedure: standard follow-up care
    Sponsors:   Tufts Medical Center;   National Cancer Institute (NCI)
    Recruiting - verified March 2010
  • Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer

    Conditions:   Leukemia;   Lymphoma;   Myelodysplastic Syndromes
    Interventions:   Drug: busulfan;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Drug: tacrolimus;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation
    Sponsor:   Northside Hospital, Inc.
    Recruiting - verified March 2010
  • Perceptions of Burden in Patients With Late-Stage Cancer and Their Caregivers

    Conditions:   Chronic Myeloproliferative Disorders;   Depression;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Psychosocial Effects of Cancer and Its Treatment;   Unspecified Adult Solid Tumor, Protocol Specific
    Interventions:   Other: medical chart review;   Other: questionnaire administration;   Procedure: psychosocial assessment and care
    Sponsors:   Cancer Institute of New Jersey;   National Cancer Institute (NCI)
    Recruiting - verified August 2008
  • Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections

    Condition:   Cancer
    Interventions:   Biological: cytomegalovirus IE-1-specific cytotoxic T lymphocytes;   Biological: cytomegalovirus pp65-specific cytotoxic T lymphocytes;   Biological: therapeutic allogeneic lymphocytes;   Genetic: polymerase chain reaction;   Other: flow cytometry;   Other: immunological diagnostic method;   Other: laboratory biomarker analysis
    Sponsors:   Milton S. Hershey Medical Center;   National Cancer Institute (NCI)
    Recruiting - verified December 2008
  • Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder

    Conditions:   Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
    Interventions:   Drug: cyclosporine ophthalmic emulsion;   Other: placebo
    Sponsors:   Vanderbilt-Ingram Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified July 2009
  • Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Unspecified Adult Solid Tumor, Protocol Specific
    Intervention:   Other: educational intervention
    Sponsors:   Fox Chase Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified July 2009
  • MRI Screening for Patients With Myelodysplastic Syndrome (MDS), Who Have Received Multiple Red Blood Cell Transfusions

    Condition:   Myelodysplastic Syndrome (MDS)
    Intervention:   Other: T2* Cardiac and Liver MRI
    Sponsors:   Weill Medical College of Cornell University;   Novartis Pharmaceuticals
    Recruiting - verified March 2010
  • Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Long-term Effects Secondary to Cancer Therapy in Children;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Precancerous Condition;   Unspecified Childhood Solid Tumor, Protocol Specific
    Interventions:   Other: survey administration;   Procedure: assessment of therapy complications;   Procedure: long-term screening;   Procedure: study of high risk factors
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified March 2010
  • Chemotherapy Followed by Allogeneic Stem Cell Transplantation for Hematologic Malignancies

    Condition:   Hematologic Malignancies
    Intervention:   Procedure: Chemotherapy followed by Stem Cell Transplantation
    Sponsor:   Dartmouth-Hitchcock Medical Center
    Recruiting - verified February 2010
  • Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Pain;   Precancerous Condition;   Unspecified Adult Solid Tumor, Protocol Specific
    Interventions:   Drug: methadone hydrochloride;   Drug: morphine sulfate;   Drug: oxycodone hydrochloride
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified June 2009
  • Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes
    Interventions:   Biological: filgrastim;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: umbilical cord blood transplantation;   Radiation: total-body irradiation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified July 2009
  • American Ginseng in Treating Patients With Fatigue Caused by Cancer

    Conditions:   Chronic Myeloproliferative Disorders;   Fatigue;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Precancerous Condition;   Unspecified Adult Solid Tumor, Protocol Specific
    Interventions:   Dietary Supplement: American ginseng;   Other: placebo
    Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
    Recruiting - verified March 2010
  • Imatinib Mesylate in Treating Patients With Sclerodermatous Chronic Graft-Versus-Host Disease

    Condition:   Cancer
    Interventions:   Drug: imatinib mesylate;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: confocal microscopy;   Other: flow cytometry;   Other: immunoenzyme technique;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: biopsy
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified February 2010
  • Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
    Interventions:   Biological: rituximab;   Drug: busulfan;   Drug: carmustine;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: etoposide;   Drug: fludarabine phosphate;   Drug: melphalan;   Radiation: total-body irradiation
    Sponsors:   Barbara Ann Karmanos Cancer Institute;   National Cancer Institute (NCI)
    Recruiting - verified January 2010
  • Monoclonal Antibody IMC-A12 and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer

    Conditions:   Adrenocortical Carcinoma;   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Precancerous Condition;   Sarcoma;   Unspecified Adult Solid Tumor, Protocol Specific
    Interventions:   Biological: cixutumumab;   Drug: temsirolimus
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified February 2010
  • A Safety and Dose-finding Study of JNJ-26481585 for Patients With Advanced of Refractory Leukemia or Myelodysplastic Syndrome.

    Conditions:   Leukemia, Myeloid, Acute;   Precursor Cell Lymphoblastic Leukemia-Lymphoma;   Leukemia, Myelogenous, Chronic, BCR-ABL Positive;   Myelodysplastic Syndromes;   Leukemia, Lymphocytic, Chronic, B-Cell
    Intervention:   Drug: JNJ-26481585.
    Sponsor:   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
    Recruiting - verified February 2010
  • Magnetic Acupressure in Reducing Pain in Cancer Patients Undergoing Bone Marrow Aspiration and Biopsy

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Pain;   Precancerous Condition;   Unspecified Adult Solid Tumor, Protocol Specific
    Interventions:   Other: questionnaire administration;   Procedure: acupressure therapy;   Procedure: biopsy;   Procedure: bone marrow aspiration;   Procedure: pain therapy
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified July 2009
  • Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Pain;   Precancerous Condition;   Unspecified Adult Solid Tumor, Protocol Specific
    Interventions:   Other: educational intervention;   Other: medical chart review;   Other: questionnaire administration;   Procedure: pain therapy;   Procedure: quality-of-life assessment
    Sponsors:   Vanderbilt-Ingram Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified October 2009
  • Montelukast in Treating Patients With Bronchiolitis Obliterans After Stem Cell Transplant

    Condition:   Cancer
    Interventions:   Drug: montelukast sodium;   Other: flow cytometry;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified August 2008
  • Fludarabine, Busulfan, and Alemtuzumab Followed By Donor Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disease

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Precancerous Condition
    Interventions:   Biological: alemtuzumab;   Drug: busulfan;   Drug: fludarabine phosphate;   Drug: tacrolimus;   Procedure: allogeneic hematopoietic stem cell transplantation
    Sponsor:   Baylor College of Medicine
    Recruiting - verified June 2009
  • Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant

    Condition:   Cancer
    Interventions:   Biological: anti-thymocyte globulin;   Biological: filgrastim;   Biological: rituximab;   Drug: clofarabine;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Procedure: allogeneic bone marrow transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Procedure: umbilical cord blood transplantation
    Sponsors:   Masonic Cancer Center, University of Minnesota;   National Cancer Institute (NCI)
    Recruiting - verified October 2008
  • Romiplostim Treatment of Thrombocytopenia in Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

    Conditions:   MDS;   Myelodysplastic Syndromes;   Thrombocytopenia
    Interventions:   Drug: Placebo;   Biological: Romiplostim
    Sponsor:   Amgen
    Recruiting - verified March 2010
  • T Lymphocytes in Treating Patients Undergoing a Donor Bone Marrow Transplant

    Condition:   Cancer
    Interventions:   Biological: allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes;   Genetic: polymerase chain reaction;   Other: immunological diagnostic method;   Procedure: adjuvant therapy
    Sponsor:   Baylor College of Medicine
    Recruiting - verified June 2009
  • A Myeloablative Conditioning Regimen and Total Body Irradiation Followed by the Transplantation for Patients With Hematological Malignancy

    Conditions:   Cancer;   Leukemia;   Myelodysplastic Syndrome;   Non-Hodgkin's Lymphoma
    Interventions:   Drug: Fludarabine, Cyclophosphamide;   Procedure: Transplantation
    Sponsor:   Memorial Sloan-Kettering Cancer Center
    Recruiting - verified February 2010
  • Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer

    Conditions:   Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Infection;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Precancerous Condition;   Secondary Myelofibrosis;   Small Intestine Cancer
    Interventions:   Biological: anti-thymocyte globulin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: fludarabine phosphate;   Drug: melphalan;   Drug: methotrexate;   Drug: sirolimus;   Drug: tacrolimus;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: hematopoietic stem cell transplantation;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: total-body irradiation
    Sponsors:   Beckman Research Institute;   National Cancer Institute (NCI)
    Recruiting - verified June 2009
  • Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia

    Condition:   Leukemia
    Interventions:   Biological: anti-thymocyte globulin;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: methotrexate;   Drug: methylprednisolone;   Drug: tacrolimus;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: allogeneic bone marrow transplantation
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified March 2010
  • Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

    Condition:   Cancer
    Interventions:   Drug: fentanyl sublingual spray;   Other: questionnaire administration
    Sponsor:   Insys Therapeutics Inc
    Recruiting - verified October 2008
  • Molecular Epidemiology of Therapy-related Acute Myeloid Leukemia/Myelodysplastic Syndrome (AML/MDS)

    Conditions:   Leukemia;   Myelodysplastic Syndrome
    Intervention:   Behavioral: Interview
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified March 2010
  • Chemotherapy, Donor Stem Cell Transplant, and Graft-Versus-Host Disease Prevention in Treating Patients With Advanced Hematologic Cancer or Other Disease

    Conditions:   Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes
    Interventions:   Biological: alemtuzumab;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: cytarabine;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: fludarabine phosphate;   Drug: methotrexate;   Drug: prednisone;   Drug: sirolimus;   Drug: tacrolimus;   Drug: vincristine sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified July 2009
  • Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant

    Conditions:   Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
    Interventions:   Drug: busulfan;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: etoposide;   Drug: methotrexate;   Drug: rasburicase;   Drug: sirolimus;   Drug: tacrolimus;   Other: flow cytometry;   Other: immunologic technique;   Other: laboratory biomarker analysis;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: total-body irradiation
    Sponsor:   Massachusetts General Hospital
    Recruiting - verified April 2008
  • Adult Double Cord Blood Transplant Study

    Conditions:   Cord Blood Stem Cell Transplantation;   Hematologic Malignancies
    Intervention:   Procedure: Cord blood transplantation
    Sponsor:   Center for International Blood and Marrow Transplant Research
    Recruiting - verified March 2010
  • Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy

    Condition:   Cancer
    Interventions:   Biological: cytomegalovirus pp65-specific cytotoxic T lymphocytes;   Genetic: polymerase chain reaction;   Other: flow cytometry;   Other: immunologic technique;   Other: laboratory biomarker analysis
    Sponsor:   Milton S. Hershey Medical Center
    Recruiting - verified October 2007
  • Beclomethasone in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant for Hematologic Cancer

    Conditions:   Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
    Interventions:   Drug: beclomethasone dipropionate;   Drug: methotrexate;   Drug: tacrolimus;   Other: placebo
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified July 2009
  • IV Busulfan With Allo-BMT: Study for Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome

    Conditions:   Myelodysplastic Syndrome;   Leukemia;   Acute Myeloid Leukemia
    Interventions:   Drug: Busulfan;   Drug: Fludarabine
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting - verified March 2010
  • Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia

    Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndrome;   Chronic Myeloid Leukemia
    Interventions:   Drug: Clofarabine;   Drug: Busulfan;   Drug: Fludarabine
    Sponsors:   M.D. Anderson Cancer Center;   Genzyme
    Recruiting - verified March 2010
  • Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Diseases

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes
    Interventions:   Biological: anti-thymocyte globulin;   Biological: filgrastim;   Biological: graft-versus-tumor induction therapy;   Biological: therapeutic allogeneic lymphocytes;   Drug: busulfan;   Drug: fludarabine phosphate;   Drug: melphalan;   Drug: methotrexate;   Drug: mycophenolate mofetil;   Drug: tacrolimus;   Procedure: allogeneic bone marrow transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation
    Sponsors:   Wake Forest University;   National Cancer Institute (NCI)
    Recruiting - verified June 2009
  • Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes
    Interventions:   Biological: anti-thymocyte globulin;   Biological: sargramostim;   Biological: therapeutic allogeneic lymphocytes;   Drug: busulfan;   Drug: fludarabine phosphate;   Drug: methotrexate;   Drug: tacrolimus;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation
    Sponsors:   UNC Lineberger Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified July 2008
  • Fludarabine, Busulfan, and Alemtuzumab Followed By Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Diseases

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes
    Interventions:   Biological: alemtuzumab;   Biological: therapeutic allogeneic lymphocytes;   Drug: busulfan;   Drug: fludarabine phosphate;   Drug: tacrolimus;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation
    Sponsors:   UNC Lineberger Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified July 2008
  • Education Sessions for Young Relative Stem Cell Donors

    Condition:   Cancer
    Interventions:   Other: counseling intervention;   Other: educational intervention;   Procedure: psychosocial assessment and care
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified December 2008
  • Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases

    Conditions:   Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Myelodysplastic Syndromes;   Secondary Myelofibrosis
    Interventions:   Biological: filgrastim;   Procedure: allogeneic bone marrow transplantation;   Procedure: peripheral blood stem cell transplantation
    Sponsors:   The Canadian Blood and Marrow Transplant Group;   National Cancer Institute (NCI)
    Recruiting - verified July 2009
  • Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Metastatic Cancer;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Precancerous Condition;   Secondary Myelofibrosis;   Unspecified Adult Solid Tumor, Protocol Specific
    Interventions:   Drug: pemetrexed disodium;   Other: laboratory biomarker analysis;   Other: pharmacological study
    Sponsor:   Robert H. Lurie Cancer Center
    Recruiting - verified July 2009
  • Cellular Therapy With Cord Blood Cells

    Conditions:   Multiple Myeloma;   Leukemia;   Lymphoma
    Interventions:   Drug: Fludarabine;   Drug: Melphalan;   Procedure: Umbilical Cord Blood;   Drug: Rituximab;   Other: Peripheral Blood Stem Cell Infusion
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting - verified March 2010
  • Lithium in Treating Patients With Acute Intestinal Graft-Versus-Host Disease After Donor Stem Cell Transplant

    Condition:   Cancer
    Intervention:   Drug: lithium carbonate
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified July 2009
  • Fludarabine and Total-Body Irradiation Followed By a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Secondary Myelofibrosis
    Interventions:   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: total-body irradiation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified July 2009
  • Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease

    Conditions:   Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Secondary Myelofibrosis;   Small Intestine Cancer
    Interventions:   Biological: therapeutic allogeneic lymphocytes;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: tacrolimus;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: in vitro-treated peripheral blood stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: total-body irradiation
    Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting - verified June 2009
  • Decitabine and Tretinoin in Treating Patients With Myelodysplastic Syndromes

    Condition:   Myelodysplastic Syndromes
    Interventions:   Drug: decitabine;   Drug: tretinoin;   Genetic: DNA methylation analysis;   Genetic: cytogenetic analysis;   Genetic: microarray analysis;   Other: flow cytometry;   Other: immunohistochemistry staining method
    Sponsors:   Memorial Sloan-Kettering Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified February 2010
  • Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes

    Conditions:   Leukemia;   Myelodysplastic Syndromes
    Interventions:   Drug: asparaginase;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: etoposide;   Drug: thioguanine
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified March 2010
  • Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
    Interventions:   Drug: cytarabine;   Drug: etoposide;   Drug: vorinostat;   Genetic: microarray analysis;   Genetic: protein expression analysis;   Other: pharmacological study
    Sponsors:   University of Maryland Greenebaum Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified June 2009
  • PXD101 and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
    Interventions:   Drug: azacitidine;   Drug: belinostat
    Sponsors:   University of Chicago;   National Cancer Institute (NCI)
    Recruiting - verified April 2009
  • Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed By Umbilical Cord Blood Stem Cell Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic Cancer and Other Diseases

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes
    Interventions:   Biological: filgrastim;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: umbilical cord blood transplantation;   Radiation: total-body irradiation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified December 2009
  • Clinical Evaluations and Laboratory Studies in Patients With Chronic Graft-Versus-Host Disease Who Have Undergone a Previous Donor Stem Cell Transplant

    Condition:   Cancer
    Interventions:   Other: laboratory biomarker analysis;   Other: physiologic testing;   Procedure: biopsy;   Procedure: management of therapy complications
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified September 2006
  • Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant

    Conditions:   Breast Cancer;   Chronic Myeloproliferative Disorders;   Gestational Trophoblastic Tumor;   Infection;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Neuroblastoma;   Ovarian Cancer;   Testicular Germ Cell Tumor
    Intervention:   Drug: moxifloxacin hydrochloride
    Sponsors:   OHSU Knight Cancer Institute;   National Cancer Institute (NCI)
    Recruiting - verified July 2009
  • Zoledronic Acid in Preventing Osteoporosis in Patients Undergoing Donor Stem Cell Transplant

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Osteoporosis;   Ovarian Cancer;   Testicular Germ Cell Tumor
    Interventions:   Dietary Supplement: calcium carbonate;   Dietary Supplement: calcium citrate;   Dietary Supplement: calcium glucarate;   Dietary Supplement: cholecalciferol;   Drug: calcium gluconate;   Drug: zoledronic acid
    Sponsors:   Masonic Cancer Center, University of Minnesota;   National Cancer Institute (NCI)
    Recruiting - verified October 2008
  • Azacitidine With or Without MS-275 in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia

    Conditions:   Leukemia;   Myelodysplastic Syndromes
    Interventions:   Drug: azacitidine;   Drug: entinostat
    Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified March 2010
  • Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant

    Conditions:   Kidney Cancer;   Leukemia;   Lymphoma;   Myelodysplastic Syndromes;   Neuroblastoma;   Pulmonary Complications;   Sarcoma
    Interventions:   Biological: etanercept;   Drug: methylprednisolone
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified March 2010
  • Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing an Umbilical Cord Blood Transplant for Hematologic Cancer

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes
    Interventions:   Biological: filgrastim;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: umbilical cord blood transplantation;   Radiation: total-body irradiation
    Sponsors:   Masonic Cancer Center, University of Minnesota;   National Cancer Institute (NCI)
    Recruiting - verified October 2008
  • Donor Natural Killer Cell Infusion in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Acute Myeloid Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes

    Conditions:   Leukemia;   Myelodysplastic Syndromes
    Interventions:   Biological: aldesleukin;   Biological: therapeutic allogeneic lymphocytes;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: total-body irradiation
    Sponsors:   Masonic Cancer Center, University of Minnesota;   National Cancer Institute (NCI)
    Recruiting - verified February 2010
  • Combination Chemotherapy and Radiation Therapy Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer, Metastatic Breast Cancer, or Kidney Cancer

    Conditions:   Breast Cancer;   Chronic Myeloproliferative Disorders;   Kidney Cancer;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
    Interventions:   Biological: CD4+CD25+ regulatory T cells;   Biological: anti-thymocyte globulin;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: total-body irradiation
    Sponsors:   Masonic Cancer Center, University of Minnesota;   National Cancer Institute (NCI)
    Recruiting - verified September 2009
  • Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant

    Condition:   Cancer
    Interventions:   Procedure: music therapy;   Procedure: psychosocial assessment and care;   Procedure: quality-of-life assessment
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI);   National Institute of Nursing Research (NINR)
    Recruiting - verified March 2010
  • Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Unusual Cancers of Childhood
    Interventions:   Biological: anti-thymocyte globulin;   Biological: filgrastim;   Biological: therapeutic allogeneic lymphocytes;   Drug: busulfan;   Drug: carmustine;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: cytarabine;   Drug: etoposide;   Drug: fludarabine phosphate;   Drug: melphalan;   Drug: methotrexate;   Drug: methylprednisolone;   Drug: mycophenolate mofetil;   Drug: tacrolimus;   Procedure: peripheral blood stem cell transplantation;   Procedure: umbilical cord blood transplantation;   Radiation: radiation therapy
    Sponsors:   OHSU Knight Cancer Institute;   National Cancer Institute (NCI)
    Recruiting - verified June 2007
  • Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic Cancer

    Conditions:   Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
    Interventions:   Biological: graft-versus-tumor induction therapy;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: umbilical cord blood transplantation;   Radiation: radiation therapy
    Sponsor:   James P. Wilmot Cancer Center
    Recruiting - verified June 2007
  • Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Precancerous Condition
    Interventions:   Biological: therapeutic allogeneic lymphocytes;   Drug: busulfan;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: peripheral blood stem cell transplantation;   Radiation: radiation therapy
    Sponsors:   OHSU Knight Cancer Institute;   National Cancer Institute (NCI)
    Recruiting - verified January 2009
  • Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes
    Interventions:   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Drug: tacrolimus;   Procedure: allogeneic bone marrow transplantation;   Radiation: radiation therapy
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified March 2010
  • Combination Chemotherapy, Tacrolimus, and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant For Hematologic Cancer

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes
    Interventions:   Drug: busulfan;   Drug: cyclophosphamide;   Drug: mycophenolate mofetil;   Drug: tacrolimus;   Procedure: allogeneic bone marrow transplantation;   Procedure: bone marrow ablation with stem cell support
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified March 2010
  • Alemtuzumab, Fludarabine, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
    Interventions:   Biological: alemtuzumab;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: peripheral blood stem cell transplantation;   Radiation: radiation therapy
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified July 2009
  • Pentostatin and Donor White Blood Cells in Preventing Graft Rejection in Cancer Patients Who Have Undergone Donor Stem Cell Transplantation

    Conditions:   Breast Cancer;   Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Neuroblastoma;   Ovarian Cancer;   Sarcoma;   Testicular Germ Cell Tumor
    Interventions:   Biological: therapeutic allogeneic lymphocytes;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Drug: pentostatin
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified July 2009
  • Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer

    Conditions:   Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
    Interventions:   Biological: graft-versus-tumor induction therapy;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Drug: tacrolimus;   Procedure: peripheral blood stem cell transplantation;   Radiation: radiation therapy
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified December 2009
  • Study of Late-Occurring Complications in Childhood Cancer Survivors

    Condition:   Cancer
    Interventions:   Genetic: cytogenetic analysis;   Genetic: mutation analysis;   Genetic: polymorphism analysis;   Other: questionnaire administration
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified March 2010
  • T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
    Interventions:   Biological: filgrastim;   Biological: graft-versus-tumor induction therapy;   Biological: rituximab;   Biological: therapeutic allogeneic lymphocytes;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: cytarabine;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: fludarabine phosphate;   Drug: prednisone;   Drug: vincristine sulfate;   Procedure: peripheral blood stem cell transplantation
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified July 2009
  • Sirolimus in Preventing Graft-Versus-Host Disease in Patients With Hematologic Malignancies Who Are Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

    Conditions:   Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
    Interventions:   Biological: therapeutic allogeneic lymphocytes;   Drug: sirolimus
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified November 2007
  • Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Allogeneic Transplantation

    Conditions:   Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Kidney Cancer;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Neuroblastoma;   Ovarian Cancer;   Sarcoma;   Testicular Germ Cell Tumor
    Intervention:   Biological: therapeutic allogeneic lymphocytes
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified December 2009
  • Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
    Interventions:   Biological: anti-thymocyte globulin;   Biological: filgrastim;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Procedure: umbilical cord blood transplantation;   Drug: methylprednisolone
    Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified March 2010
  • Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Aplastic Anemia

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
    Interventions:   Biological: anti-thymocyte globulin;   Biological: graft-versus-tumor induction therapy;   Biological: sargramostim;   Biological: therapeutic allogeneic lymphocytes;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: methylprednisolone;   Drug: mycophenolate mofetil;   Drug: tacrolimus;   Procedure: allogeneic bone marrow transplantation;   Procedure: peripheral blood stem cell transplantation;   Procedure: umbilical cord blood transplantation
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
    Recruiting - verified June 2009
  • Screening Individuals and Families at High Risk for Hematologic Cancers

    Conditions:   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
    Interventions:   Genetic: genetic linkage analysis;   Genetic: microarray analysis;   Other: counseling intervention;   Other: laboratory biomarker analysis;   Other: questionnaire administration;   Procedure: evaluation of cancer risk factors
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified April 2007
  • Genetic Study of Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Multiple Myeloma

    Conditions:   Leukemia;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
    Interventions:   Genetic: chromosomal translocation analysis;   Genetic: cytogenetic analysis
    Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
    Recruiting - verified March 2010
  • Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation

    Conditions:   Chronic Myeloproliferative Disorders;   Kidney Cancer;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Neuroblastoma;   Oral Complications;   Ovarian Cancer;   Pain;   Sarcoma
    Interventions:   Procedure: management of therapy complications;   Procedure: pain therapy
    Sponsor:   Medical College of Wisconsin
    Recruiting - verified June 2009
  • Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Nonmalignant Neoplasm;   Unspecified Adult Solid Tumor, Protocol Specific;   Unspecified Childhood Solid Tumor, Protocol Specific
    Interventions:   Biological: anti-thymocyte globulin;   Drug: busulfan;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: fludarabine phosphate;   Drug: melphalan;   Drug: thiotepa;   Radiation: total-body irradiation
    Sponsor:   Roswell Park Cancer Institute
    Recruiting - verified June 2009
  • Chemotherapy and Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Disease or Hematologic Cancer

    Conditions:   Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
    Interventions:   Biological: anti-thymocyte globulin;   Biological: therapeutic allogeneic lymphocytes;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Procedure: peripheral blood stem cell transplantation
    Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting - verified June 2009

Main Menu

Find Clinical Trials